{"success":true,"data":{"pressRelease":{"id":"167279","rtpr_id":"nPnj3Zxka-20261013","ticker":"PLSM","exchange":"NASDAQ","all_tickers":["PLSM"],"title":"Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer","author":"PR Newswire","published_at":"2026-10-13T11:00:13.891Z","article_body":"Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer\nPR Newswire\n\nRAMAT GAN, Israel, Oct. 13, 2026\n\nExpanded commercial team to accelerate U.S. growth as demand for accessible\nprenatal care and federal rural health investments create new opportunities\n\nRAMAT GAN, Israel, Oct. 13, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ:\nPLSM) (TASE: PLSM) (\"Pulsenmore\" or the \"Company\"), a pioneer in\npatient-operated home ultrasound technology, today announced the appointment\nof David Woods as Chief Commercial Officer (CCO), alongside the expansion of\nits U.S. commercial team, as the Company scales its presence in the U.S.\nhealthcare market.\n\nDavid Woods brings more than 25 years of medtech leadership experience, most\nrecently serving as CCO at Creo Medical. Previously, he held senior executive\nroles at PENTAX Medical, including President and CEO of PENTAX Medical\nAmericas.\n\nFollowing FDA De Novo authorization of its home prenatal ultrasound system,\nPulsenmore has launched U.S. commercial operations and entered a strategic\ncollaboration with Ouma Health. The Company's technology is designed to enable\npregnant women to perform ultrasound scans at home, with remote physician\ninterpretation, helping healthcare providers extend prenatal monitoring beyond\ntraditional care settings.\n\nPulsenmore sees significant commercial potential in addressing gaps in\nmaternal care access, particularly in underserved and rural communities. As\npart of its U.S. growth strategy, the Company is exploring opportunities\nassociated with the U.S. federal Rural Health Transformation Program (RHTP),\nwhich supports state-led initiatives to improve rural healthcare access,\nincluding maternal health services and technology-enabled care.\n\n\"We believe the U.S. market presents a significant opportunity for Pulsenmore,\nwith growing recognition of the need to bring maternal care closer to\npatients,\" said Dr. Elazar Sonnenschein, CEO and founder of Pulsenmore. \"Our\ncommercial progress, together with new investments in rural healthcare,\nreinforces our commitment to this market. Expanding our commercial team and\nbringing David on board reflect our focus on translating this opportunity into\nsustainable growth.\"\n\n\"I'm excited to join Pulsenmore and support its commitment to advancing\nwomen's health. Bringing ultrasound into the home has the potential to make\nmaternal care more accessible and connected, helping women feel informed and\nsupported throughout their pregnancies. I look forward to contributing my\nexperience to help expand that impact,\" said David Woods, incoming Chief\nCommercial Officer of Pulsenmore.\n\nAbout Pulsenmore\n\nPulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM) is a healthcare technology\ncompany focused on transforming women's healthcare through remote ultrasound\nand telemedicine solutions. The Company develops patient-operated ultrasound\nsystems that enable remote clinical assessment and monitoring, with\napplications across pregnancy and fertility care.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements. In particular,\nstatements using words such as \"may,\" \"seek,\" \"will,\" \"consider,\" \"likely,\"\n\"assume,\" \"estimate,\" \"expect,\" \"anticipate,\" \"intend,\" \"believe,\"\n\"contemplate,\" \"do not believe,\" \"aim,\" \"goal,\" \"due,\" \"predict,\" \"plan,\"\n\"project,\" \"continue,\" \"potential,\" \"positioned,\" \"guidance,\" \"objective,\"\n\"outlook,\" \"trends,\" \"future,\" \"could,\" \"would,\" \"should,\" \"target,\" \"on\ntrack\" or their negatives or variations, and similar terminology and words of\nsimilar import, generally involve future or forward-looking statements. Such\nforward-looking statements include, but are not limited to, statements\nregarding the Company's plans to expand its commercial organization and scale\nits presence in the U.S. healthcare market; the expected contributions of\nDavid Woods and the Company's expanded commercial team to the Company's growth\nstrategy; the commercialization, market adoption and potential benefits of the\nCompany's home prenatal ultrasound system and remote monitoring platform; the\nCompany's strategic collaboration with Ouma Health; the Company's ability to\nexpand access to prenatal and maternal care, including in underserved and\nrural communities; opportunities that may arise from the federal Rural Health\nTransformation Program and other investments in rural healthcare; and the\npotential size, growth and commercial opportunities of the U.S. maternal\nhealthcare market.\n\nForward-looking statements reflect Pulsenmore's current views, plans, or\nexpectations with respect to future events or financial performance. They are\ninherently subject to significant business, economic, competitive, and other\nrisks, uncertainties, and contingencies. Forward-looking statements are based\non Pulsenmore's current expectations and are subject to inherent\nuncertainties, risks and assumptions that are difficult to predict, including,\nbut not limited to, the following: the Company's lack of operating history;\nthe Company's current and future capital requirements and the Company's belief\nthat its existing cash will be sufficient to fund its operations for more than\none year from the date that the financial statements are issued; the Company's\nability to manufacture, market and sell its products and to generate revenues;\nthe Company's ability to maintain its relationships with key partners and grow\nrelationships with new partners; the Company's ability to maintain or protect\nthe validity of its U.S. and other patents and other intellectual property;\nthe Company's ability to launch and penetrate markets in new locations and new\nmarket segments; the Company's ability to retain key executive members and\nhire additional personnel; the Company's ability to maintain and expand\nintellectual property rights; interpretations of current laws and the passages\nof future laws; the Company's ability to achieve greater regulatory compliance\nneeded in existing and new markets; the Company's ability to achieve key\nperformance milestones in its planned operational testing; the Company's\nability to establish adequate sales, marketing and distribution channels;\nsecurity, political and economic instability in the Middle East that could\nharm its business; and acceptance of the Company's business model by\ninvestors. Further, certain forward-looking statements are based on\nassumptions as to future events that may not prove to be accurate. For a more\ndetailed description of the risks and uncertainties affecting the Company,\nreference is made to the Company's reports filed from time to time with the\nSEC, including, but not limited to, the risks, uncertainties and other factors\nincluded in the Company's Annual Report on Form 20-F, filed with the SEC on\nMarch 30, 2026. The inclusion of forward-looking statements in this or any\nother communication should not be considered as a representation by Pulsenmore\nor any other person that current plans or expectations will be achieved.\nForward-looking statements speak only as of the date on which they are made,\nand Pulsenmore undertakes no obligation to publicly update or revise any\nforward-looking statement, whether as a result of new information, future\ndevelopments, or otherwise, except as otherwise required by law.\n\nInvestor Contact:\nMiriSegal-Scharia\nMS-IR LLC\nmsegal@ms-ir.com (mailto:msegal@ms-ir.com)\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/pulsenmore-strengthens-us-commercial-leadership-appoints-med-tech-veteran-david-woods-as-chief-commercial-officer-302906744.html\n(https://www.prnewswire.com/news-releases/pulsenmore-strengthens-us-commercial-leadership-appoints-med-tech-veteran-david-woods-as-chief-commercial-officer-302906744.html)\n\nSOURCE Pulsenmore Ltd.\n\n\n\n1-917-607-8654\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1815739/Pulsenmore-Logo.jpg?id=OA3015124\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnj3Zxka-20261013","title":"Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer","author":"PR Newswire","ticker":"PLSM","created":"2026-10-13T11:00:13.891Z","tickers":["PLSM"],"exchange":"NASDAQ","article_body":"Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer\nPR Newswire\n\nRAMAT GAN, Israel, Oct. 13, 2026\n\nExpanded commercial team to accelerate U.S. growth as demand for accessible\nprenatal care and federal rural health investments create new opportunities\n\nRAMAT GAN, Israel, Oct. 13, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ:\nPLSM) (TASE: PLSM) (\"Pulsenmore\" or the \"Company\"), a pioneer in\npatient-operated home ultrasound technology, today announced the appointment\nof David Woods as Chief Commercial Officer (CCO), alongside the expansion of\nits U.S. commercial team, as the Company scales its presence in the U.S.\nhealthcare market.\n\nDavid Woods brings more than 25 years of medtech leadership experience, most\nrecently serving as CCO at Creo Medical. Previously, he held senior executive\nroles at PENTAX Medical, including President and CEO of PENTAX Medical\nAmericas.\n\nFollowing FDA De Novo authorization of its home prenatal ultrasound system,\nPulsenmore has launched U.S. commercial operations and entered a strategic\ncollaboration with Ouma Health. The Company's technology is designed to enable\npregnant women to perform ultrasound scans at home, with remote physician\ninterpretation, helping healthcare providers extend prenatal monitoring beyond\ntraditional care settings.\n\nPulsenmore sees significant commercial potential in addressing gaps in\nmaternal care access, particularly in underserved and rural communities. As\npart of its U.S. growth strategy, the Company is exploring opportunities\nassociated with the U.S. federal Rural Health Transformation Program (RHTP),\nwhich supports state-led initiatives to improve rural healthcare access,\nincluding maternal health services and technology-enabled care.\n\n\"We believe the U.S. market presents a significant opportunity for Pulsenmore,\nwith growing recognition of the need to bring maternal care closer to\npatients,\" said Dr. Elazar Sonnenschein, CEO and founder of Pulsenmore. \"Our\ncommercial progress, together with new investments in rural healthcare,\nreinforces our commitment to this market. Expanding our commercial team and\nbringing David on board reflect our focus on translating this opportunity into\nsustainable growth.\"\n\n\"I'm excited to join Pulsenmore and support its commitment to advancing\nwomen's health. Bringing ultrasound into the home has the potential to make\nmaternal care more accessible and connected, helping women feel informed and\nsupported throughout their pregnancies. I look forward to contributing my\nexperience to help expand that impact,\" said David Woods, incoming Chief\nCommercial Officer of Pulsenmore.\n\nAbout Pulsenmore\n\nPulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM) is a healthcare technology\ncompany focused on transforming women's healthcare through remote ultrasound\nand telemedicine solutions. The Company develops patient-operated ultrasound\nsystems that enable remote clinical assessment and monitoring, with\napplications across pregnancy and fertility care.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements. In particular,\nstatements using words such as \"may,\" \"seek,\" \"will,\" \"consider,\" \"likely,\"\n\"assume,\" \"estimate,\" \"expect,\" \"anticipate,\" \"intend,\" \"believe,\"\n\"contemplate,\" \"do not believe,\" \"aim,\" \"goal,\" \"due,\" \"predict,\" \"plan,\"\n\"project,\" \"continue,\" \"potential,\" \"positioned,\" \"guidance,\" \"objective,\"\n\"outlook,\" \"trends,\" \"future,\" \"could,\" \"would,\" \"should,\" \"target,\" \"on\ntrack\" or their negatives or variations, and similar terminology and words of\nsimilar import, generally involve future or forward-looking statements. Such\nforward-looking statements include, but are not limited to, statements\nregarding the Company's plans to expand its commercial organization and scale\nits presence in the U.S. healthcare market; the expected contributions of\nDavid Woods and the Company's expanded commercial team to the Company's growth\nstrategy; the commercialization, market adoption and potential benefits of the\nCompany's home prenatal ultrasound system and remote monitoring platform; the\nCompany's strategic collaboration with Ouma Health; the Company's ability to\nexpand access to prenatal and maternal care, including in underserved and\nrural communities; opportunities that may arise from the federal Rural Health\nTransformation Program and other investments in rural healthcare; and the\npotential size, growth and commercial opportunities of the U.S. maternal\nhealthcare market.\n\nForward-looking statements reflect Pulsenmore's current views, plans, or\nexpectations with respect to future events or financial performance. They are\ninherently subject to significant business, economic, competitive, and other\nrisks, uncertainties, and contingencies. Forward-looking statements are based\non Pulsenmore's current expectations and are subject to inherent\nuncertainties, risks and assumptions that are difficult to predict, including,\nbut not limited to, the following: the Company's lack of operating history;\nthe Company's current and future capital requirements and the Company's belief\nthat its existing cash will be sufficient to fund its operations for more than\none year from the date that the financial statements are issued; the Company's\nability to manufacture, market and sell its products and to generate revenues;\nthe Company's ability to maintain its relationships with key partners and grow\nrelationships with new partners; the Company's ability to maintain or protect\nthe validity of its U.S. and other patents and other intellectual property;\nthe Company's ability to launch and penetrate markets in new locations and new\nmarket segments; the Company's ability to retain key executive members and\nhire additional personnel; the Company's ability to maintain and expand\nintellectual property rights; interpretations of current laws and the passages\nof future laws; the Company's ability to achieve greater regulatory compliance\nneeded in existing and new markets; the Company's ability to achieve key\nperformance milestones in its planned operational testing; the Company's\nability to establish adequate sales, marketing and distribution channels;\nsecurity, political and economic instability in the Middle East that could\nharm its business; and acceptance of the Company's business model by\ninvestors. Further, certain forward-looking statements are based on\nassumptions as to future events that may not prove to be accurate. For a more\ndetailed description of the risks and uncertainties affecting the Company,\nreference is made to the Company's reports filed from time to time with the\nSEC, including, but not limited to, the risks, uncertainties and other factors\nincluded in the Company's Annual Report on Form 20-F, filed with the SEC on\nMarch 30, 2026. The inclusion of forward-looking statements in this or any\nother communication should not be considered as a representation by Pulsenmore\nor any other person that current plans or expectations will be achieved.\nForward-looking statements speak only as of the date on which they are made,\nand Pulsenmore undertakes no obligation to publicly update or revise any\nforward-looking statement, whether as a result of new information, future\ndevelopments, or otherwise, except as otherwise required by law.\n\nInvestor Contact:\nMiriSegal-Scharia\nMS-IR LLC\nmsegal@ms-ir.com (mailto:msegal@ms-ir.com)\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/pulsenmore-strengthens-us-commercial-leadership-appoints-med-tech-veteran-david-woods-as-chief-commercial-officer-302906744.html\n(https://www.prnewswire.com/news-releases/pulsenmore-strengthens-us-commercial-leadership-appoints-med-tech-veteran-david-woods-as-chief-commercial-officer-302906744.html)\n\nSOURCE Pulsenmore Ltd.\n\n\n\n1-917-607-8654\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1815739/Pulsenmore-Logo.jpg?id=OA3015124\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-13T11:00:13.95320387Z","server_sent_at_ms":1791889213953},"received_at":"2026-10-13T11:00:14.004Z","source_url":"https://www.prnewswire.com/news-releases/pulsenmore-strengthens-us-commercial-leadership-appoints-med-tech-veteran-david-woods-as-chief-commercial-officer-302906744.html"},"analysis":{"id":"155584","press_release_id":"167279","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Pulsenmore appointed medtech veteran David Woods as Chief Commercial Officer and is expanding its U.S. commercial team as it scales stateside operations.\n\nWoods brings 25+ years of medtech experience, most recently as CCO of Creo Medical and previously President and CEO of PENTAX Medical Americas.\n\nThe hire follows FDA De Novo authorization of the company's home prenatal ultrasound system and a strategic collaboration with Ouma Health; Pulsenmore is also exploring opportunities tied to the federal Rural Health Transformation Program.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Commercial leadership hire signals U.S. go-to-market push post-De Novo authorization; watch for revenue traction and RHTP funding opportunities."},"keyFigures":{},"quotedText":"We believe the U.S. market presents a significant opportunity for Pulsenmore, with growing recognition of the need to bring maternal care closer to patients","namedEntities":{"people":[{"name":"David Woods","role":"Chief Commercial Officer (incoming)"},{"name":"Dr. Elazar Sonnenschein","role":"CEO and founder"}],"products":["home prenatal ultrasound system"],"companies":[{"name":"Pulsenmore Ltd.","ticker":"PLSM"},{"name":"Creo Medical","relationship":"Woods' prior employer"},{"name":"PENTAX Medical","relationship":"Woods' prior employer"},{"name":"Ouma Health","relationship":"strategic collaboration partner"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Routine executive appointment (CCO hire) paired with commercial team expansion at a small-cap medtech. Not a CEO/CFO departure; supportive of the U.S. commercialization ramp but not market-moving."},"tickerRelevance":{"others":[],"primary":"PLSM"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"executive_hire_non-C-suite-critical","sectorWeight":"medtech-commercialization","householdBrandBoost":false,"retailFavoriteBoost":false}},"event_type":"executive_change","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Pulsenmore appointed medtech veteran David Woods as Chief Commercial Officer and is expanding its U.S. commercial team as it scales stateside operations.\n\nWoods brings 25+ years of medtech experience, most recently as CCO of Creo Medical and previously President and CEO of PENTAX Medical Americas.\n\nThe hire follows FDA De Novo authorization of the company's home prenatal ultrasound system and a strategic collaboration with Ouma Health; Pulsenmore is also exploring opportunities tied to the federal Rural Health Transformation Program.","key_figures":{},"named_entities":{"people":[{"name":"David Woods","role":"Chief Commercial Officer (incoming)"},{"name":"Dr. Elazar Sonnenschein","role":"CEO and founder"}],"products":["home prenatal ultrasound system"],"companies":[{"name":"Pulsenmore Ltd.","ticker":"PLSM"},{"name":"Creo Medical","relationship":"Woods' prior employer"},{"name":"PENTAX Medical","relationship":"Woods' prior employer"},{"name":"Ouma Health","relationship":"strategic collaboration partner"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T11:00:26.595Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"executive_hire_non-C-suite-critical","sectorWeight":"medtech-commercialization","householdBrandBoost":false,"retailFavoriteBoost":false}},"durationMs":4945,"modelName":"glm-5.3-flashx"}}